['human immunodeficiency virus']
['3bnc117', '10-1074', 'placebo']

        Inclusion Criteria:

          -  Males and females, age 18 to 65.

          -  Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent
             with low risk of HIV exposure.

          -  If sexually active male or female, and participating in sexual activity that could
             lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom
             with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based
             contraceptive with condom) for the duration of the study.

        Exclusion Criteria:

          -  Confirmed HIV-1 or HIV-2 infection.

          -  History of immunodeficiency or autoimmune disease; use of systemic corticosteroids,
             immunosuppressive anti-cancer, or other medications considered significant by the
             trial physician within the last 6 months.

          -  Any clinically significant acute or chronic medical condition (such as autoimmune
             diseases) that in the opinion of the investigator would preclude participation.

          -  Within the 12 months prior to enrollment, the participant has a history of sexually
             transmitted infection.

          -  Chronic Hepatitis B or Hepatitis C infection.

          -  Laboratory abnormalities in the parameters listed:

          -  Absolute neutrophil count ≤ 2,000;

          -  Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;

          -  Platelet count ≤ 125,000;

          -  Alanine Aminotransferase (ALT) ≥ 1.25 x ULN; Aspartate Aminotransferase (AST) ≥ 1.25 x
             ULN;

          -  Alkaline phosphatase ≥ 1.5 x ULN

          -  Total bilirubin > 1.0 x ULN;

          -  Creatinine ≥1.1 x ULN;

          -  Pregnancy or lactation.

          -  Any vaccination within 14 days prior to infusion

          -  Receipt of any experimental HIV vaccine in the past.

          -  History of severe reaction to a vaccine or drug infusion or history of severe allergic
             reactions.

          -  Participation in another clinical study of an investigational product currently or
             within past 12 weeks, or expected participation during this study.
      